Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
This family of transporters has previously been classified as part of the atypical major facilitator superfamily (MSF) protein superfamily [1,8-11]. The atypical SLCs share sequence similarities and phylogenetic ancestry with other SLCs, and they have historically been classified in to subfamilies (also referred to as atypical MFS transporter families (AMTF1-15)) based on phylogenetic, sequence and structural analyses [9].
synaptic vesicle glycoprotein 2A / SLC22B1 C Show summary » More detailed page |
Database page citation (select format):
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Transporters. Br J Pharmacol. 180 Suppl 2:S374-469.
There are three human synaptic vesicle glycoprotein 2 family members, SV2A, SV2B and SV2C. They have transmembrane transporter activity and can be classified in to the SLC superfamily of solute carriers in subfamily SLC22, as SCL22B1, B2 and B3 respectively. SV2A (SCL22B1) has been identified as the brain binding-site for the antiepileptic drugs levetiracetam [3-4] and brivaracetam [6].